Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by FUNDA MERIC-BERNSTAM and MILIND JAVLE.
FUNDA MERIC-BERNSTAM
Connection Strength
3.831
MILIND JAVLE
  1. Utilizing Patient-derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. Clin Cancer Res. 2024 Nov 08.
    View in: PubMed
    Score: 0.249
  2. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. NPJ Precis Oncol. 2024 Jul 31; 8(1):166.
    View in: PubMed
    Score: 0.245
  3. Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov. 2024 May 01; 14(5):828-845.
    View in: PubMed
    Score: 0.240
  4. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist. 2024 Apr 04; 29(4):e514-e525.
    View in: PubMed
    Score: 0.239
  5. Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. J Immunother Precis Oncol. 2024 Feb; 7(1):7-17.
    View in: PubMed
    Score: 0.236
  6. Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024 02; 80(2):322-334.
    View in: PubMed
    Score: 0.233
  7. Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. J Immunother Precis Oncol. 2022 Feb; 5(1):26-30.
    View in: PubMed
    Score: 0.206
  8. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study. Cancer Discov. 2022 02; 12(2):402-415.
    View in: PubMed
    Score: 0.201
  9. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021 09; 22(9):1290-1300.
    View in: PubMed
    Score: 0.199
  10. Next generation sequencing for biliary tract cancers. Expert Rev Gastroenterol Hepatol. 2021 May; 15(5):471-474.
    View in: PubMed
    Score: 0.193
  11. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep. 2020 12 16; 10(1):22087.
    View in: PubMed
    Score: 0.190
  12. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.
    View in: PubMed
    Score: 0.178
  13. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.176
  14. Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. JCO Precis Oncol. 2018 Nov; 2:1-12.
    View in: PubMed
    Score: 0.164
  15. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016 Dec 15; 122(24):3838-3847.
    View in: PubMed
    Score: 0.142
  16. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014; 9(12):e115383.
    View in: PubMed
    Score: 0.126
  17. KRAS Allelic Variants in Biliary Tract Cancers. JAMA Netw Open. 2024 May 01; 7(5):e249840.
    View in: PubMed
    Score: 0.060
  18. RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study. Mol Cancer. 2024 03 26; 23(1):64.
    View in: PubMed
    Score: 0.060
  19. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol. 2023 Feb 18; 7(1):19.
    View in: PubMed
    Score: 0.055
  20. Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precis Oncol. 2022 02; 6:e2100197.
    View in: PubMed
    Score: 0.051
  21. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2022 02; 75(2):297-308.
    View in: PubMed
    Score: 0.051
  22. Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. J Immunother Precis Oncol. 2021 May; 4(2):45-52.
    View in: PubMed
    Score: 0.049
  23. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. JCO Precis Oncol. 2020; 4.
    View in: PubMed
    Score: 0.046
  24. Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surg Nutr. 2019 Dec; 8(6):604-614.
    View in: PubMed
    Score: 0.044
  25. Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.044
  26. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.
    View in: PubMed
    Score: 0.041
  27. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther. 2018 07; 17(7):1595-1601.
    View in: PubMed
    Score: 0.040
  28. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget. 2017 Oct 20; 8(50):87163-87173.
    View in: PubMed
    Score: 0.038
  29. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.